Filing Analysis
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the three and nine months ended September 30, 2024.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial performance.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
RxSight, Inc. filed an 8-K to announce its quarterly results of operations and financial condition for the periods ended June 30, 2024.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Filing date: August 5, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial performance.
RxSight, Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the re-election of three Class III directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Quorum represented approximately 80.8% of outstanding shares (30,022,322 shares out of 37,173,544 total).
- Julie B. Andrews, Robert J. Palmisano, and Tamara R. Fountain, M.D. were re-elected to the Board as Class III directors.
- Stockholders approved executive compensation on an advisory basis.
- Stockholders voted for 'ONE YEAR' frequency for future advisory votes on executive compensation.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
RxSight, Inc. entered into an underwriting agreement to conduct a public offering of 1,785,714 shares of common stock at $56.00 per share. The offering is expected to generate approximately $93.2 million in net proceeds and is anticipated to close on May 13, 2024.
🚩 Red Flags
- Equity dilution: The issuance of over 1.7 million new shares will dilute existing shareholders.
📋 Key Facts
- Offering size: 1,785,714 shares of common stock.
- Offering price: $56.00 per share.
- Underwriters include BofA Securities, Inc. as representative.
- Expected net proceeds: Approximately $93.2 million after expenses and discounts.
- Includes an over-allotment option for underwriters to purchase up to 267,857 additional shares.
- Lock-up period: Executive officers and directors are subject to a 60-day lock-up agreement.
RxSight, Inc. filed an 8-K to announce its quarterly results of operations and financial condition for the three months ended March 31, 2024.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Three months ended March 31, 2024
- The filing serves to provide the quarterly earnings press release (Exhibit 99.1)
RxSight, Inc. entered into one new lease and two amendments to existing leases for its facilities in Aliso Viejo, California, to secure long-term access and expand manufacturing capacity.
🚩 Red Flags
- Increased long-term fixed operating obligations (lease liabilities).
📋 Key Facts
- Entered into a new lease (125 Columbia Lease) with BML Management, LLC for ~26,825 sq. ft., starting June 1, 2024, ending Jan 31, 2031.
- Base rent for the new lease is $41,579 per month.
- Amended '5 Columbia' lease to extend term by 70 months (April 1, 2025 – Jan 31, 2031) with base rent of $30,701/month.
- Amended '100 Columbia' lease to extend term by 76 months (Oct 1, 2024 – Jan 31, 2031) with base rent of $64,843/month.
- Total future minimum lease payments under these agreements amount to approximately $10.8 million.
- Lease terms include multiple 60-month extension options for each facility.
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the three and twelve months ended December 31, 2023.
📋 Key Facts
- Report date: February 28, 2024
- Reporting period: Three and twelve months ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 regarding financial results.
RxSight, Inc. issued an 8-K to announce the release of preliminary unaudited financial and operational results for the fourth quarter and full year of 2023.
📋 Key Facts
- The filing relates to preliminary unaudited Q4 and Full Year 2023 financial/operational results.
- Results were announced via press release on January 7, 2024.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.